Singapore: Clinical stage biotech Lion TCR bags $20m from Yashang Capital, others

Singapore-based clinical stage biotech firm Lion TCR has raised $20 million in a Series A funding round from new investors Yashang Capital and US-based early stage investor Westlake Ventures Capital apart from undisclosed existing investors.

Lion TCR is a company focused on the development of T cell receptor (TCR)-T cell therapy against life-threatening viral infections and viral-related cancers pertinent in Asia.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter